Articles written by: Tyler Harlow

Osmotica Pharmaceuticals plc (OSMT)’s Financial Results Comparing With Ophthotech Corporation (NASDAQ:OPHT)

Both Osmotica Pharmaceuticals plc (NASDAQ:OSMT) and Ophthotech Corporation (NASDAQ:OPHT) are each other’s competitor in the Biotechnology industry. Thus the contrast of their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Osmotica Pharmaceuticals plc 274.34M […]

$0.15 EPS Expected for Viomi Technology Co., Ltd (VIOT); NORTHAM PLATINUM PROPERTY LTD ORDINARY S (NMPNF) Shorts Decreased By 1.58%

$0.15 EPS Expected for Viomi Technology Co., Ltd (VIOT); NORTHAM PLATINUM PROPERTY LTD ORDINARY S (NMPNF) Shorts Decreased By 1.58%

Analysts expect Viomi Technology Co., Ltd (NASDAQ:VIOT) to report $0.15 EPS on February, 25.VIOT’s profit would be $10.39 million giving it 13.07 P/E if the $0.15 EPS is correct. After having $-1.02 EPS previously, Viomi Technology Co., Ltd’s analysts see -114.71% EPS growth. The stock increased 1.03% or $0.08 during […]

Bloom Tree Partners Increases Position in Alibaba Group Hldg LTD (BABA); Shareholder Murphy Pohlad Asset Management Boosted Federated Invs Pa (FII) Position

Bloom Tree Partners Increases Position in Alibaba Group Hldg LTD (BABA); Shareholder Murphy Pohlad Asset Management Boosted Federated Invs Pa (FII) Position

Bloom Tree Partners Llc increased its stake in Alibaba Group Hldg Ltd (BABA) by 29.01% based on its latest 2018Q3 regulatory filing with the SEC. Bloom Tree Partners Llc bought 86,034 shares as the company’s stock declined 3.15% with the market. The hedge fund held 382,599 shares of the business […]

Divi Project (DIVI) hits new $-0.0013289328 price after -47.39% decline for a day

It was bad day for Divi Project (DIVI), as it declined by $-0.0013289328 or -47.39%, touching $0.0014751264. Global Crypto Experts believe that Divi Project (DIVI) is looking for the $0.00162263904 goal. According to 8 analysts could reach $0.00391785059802519. The highest price was $0.0028040592 and lowest of $0.0014751264 for January 31 […]

Ultragenyx Pharmaceutical Inc. (RARE)’s Financial Results Comparing With Audentes Therapeutics Inc. (NASDAQ:BOLD)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Audentes Therapeutics Inc. (NASDAQ:BOLD) compete against each other in the Biotechnology sector. We will compare them and contrast their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ultragenyx Pharmaceutical […]